Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.

Slides:



Advertisements
Similar presentations
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Advertisements

Medication Assisted Treatment Michael Palladini, RPh MBA CAC
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Swinomish Wellness Program
Sublingual Buprenorphine and Pain
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Developments in Community - Based Drug Treatments Lesley Peters
Opiate Substitution Treatment: An Overview Ron Jackson, M.S.W. Evergreen Treatment Services Seattle, WA.
INTRODUCTION TO ADDICTION Benjamin R. Nordstrom, M.D., Ph.D. Assistant Professor of Psychiatry Geisel School of Medicine at Dartmouth Director of Addiction.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
Buprenorphine in the treatment of addiction Matthew A. Torrington MD Clinical Research Physician UCLA: Integrated Substance Abuse Programs Matrix Institute.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
Ken Saffier, MD, Natasha Pinto, MD And Patients CCRMC/HC Noon Conference February 18, 2010.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
OPIOID SUBSTITUTION THERAPY
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
Buprenorphine Therapy in Primary Care: One Prescriber’s Experience Pittsburgh, PA August 24, 2005 Melinda Campopiano, M.D. Baron Edmond de Rothschild Chemical.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Medical issues about Methadone : What the counselor needs to know
Opiate Receptor Pharmacology
Allegheny County Overdose Prevention Coalition
Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,
Module 1 General introduction to substitution treatment.
 Methadone is prescribed to relieve moderate to severe pain that has not been relieved by non-narcotic pain relievers.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
Opioid Pharmacotherapy: An Introduction Walter Ling, MD Integrated Substance Abuse Programs (ISAP) UCLA International Symposium on Drug Abuse and Addictive.
VIVITROL INJECTIONS IN CONJUNCTION WITH THE WARREN COUNTY JAIL Coordination at many levels.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
A Revolution in Pain Pharmaceuticals 1. The Problem Opioids are the oldest and most prescribed pain drugs. They are the most powerful analgesics for treatment.
Opioid Treatment Basics for Counselors Thomas E. Freese, PhD Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance Abuse Programs.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS State of the art and new perspectives in drug addiction treatment Dr L Michel, MD, PhD Inserm U1178.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
September 2015 PHARMACOLOGY OF ADDICTIONS.  Understanding the pharmacological basis of medications used to manage dependence  Understanding how pharmacological.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Medication Assisted Treatment for Opioid Use Disorders
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Responding to the Opioid Addiction Epidemic Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for.
Medication Assisted Treatment Vijay Amarendran, MD, Dip ABAM 08/01/16.
Gregory S. Brigham, Ph.D., CEO
Medical Assisted Treatment
The intersection of medication assisted treatment and mental health
What does pharmacology have to do with treatment of heroin addiction?
Opiod analgesics 9월 흉부외과 인턴 김영재.
Medication-Assisted Therapy at Coleman Profession Services
Medication-Assisted Treatment 101: Breaking the Stigma
Pain Management: Patients Maintained on Buprenorphine
Sara Olack, MD, PhD Cecilia Lau, MD Advisor: Jane Gagliardi, MD
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Medications used in Treatment of Alcohol and Drug Use Disorders
No conflicts of interest
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Presentation transcript:

Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and University of Washington Seattle, WA

Disclosures Supported by: National Institute on Drug Abuse Clinical Trials Network Supported by: National Institute on Drug Abuse Clinical Trials Network Scientific Advisory Board, Alkermes, Inc. Scientific Advisory Board, Alkermes, Inc. Speaker, ReckittBenckiser, Inc. Speaker, ReckittBenckiser, Inc.

Medication Assisted Treatment Methadone and Buprenorphine –Pharmacology –Efficacy Starting Treatment with Agonist Replacement Therapies (START) Study –Comparing methadone and buprenorphine on Treatment retention Illicit opioid use HIV risk reduction

Methadone Pharmacokinetics and Dosing Rapidly absorbed Peak Levels in 4 hours t 1/2 =24 hours Metabolized in liver (p450 3A/4) Doses should be individualized but higher doses generally more effective

Kyle et al., 1999

Swedish Methadone Study Before Experimental Group (Methadone) Control Group (No Methadone) Gunne & Gronbladh, 1981

Swedish Methadone Study After 2 Years Experimental Group (Methadone) Control Group (No Methadone) Gunne & Gronbladh, 1981 d ab c dd a Sepsis b Sepsis and Endocarditis c Leg Amputation d In Prison

Methadone Side Effects Minimal sedation once tolerance achieved Constipation Increased Appetite/Weight Gain Lowered Libido; May decrease gonadal hormone levels Exhaustively studied in all other organ systems with no evidence of chronic harm

Properties of Buprenorphine, a µ -Opioid Partial Agonist Ceiling effect on respiratory depression High affinity for µ-opioid receptor Slowly dissociates from µ-opioid receptors Ameliorates withdrawal once underway Can precipitate withdrawal if given in temporal proximity to full agonist opioids

Efficacy: Full Agonist (Methadone) Partial Agonist (Buprenorphine), Antagonist (Naloxone) Efficacy: Full Agonist (Methadone) Partial Agonist (Buprenorphine), Antagonist (Naloxone) % Efficacy Log Dose of Opioid Full Agonist (Methadone) Partial Agonist (Buprenorphine) Antagonist (Naloxone)

Buprenorphine Pharmacology Poor oral bioavailability; given sublingually (subcutaneous implants: experimental; patch: for pain) Slow onset (Peak effects 3-6 hrs.) Long duration ( hours) Slow offset Half life > 24 hours

Zubieta et al., 2000

No. Assessed for Eligibility: 84 No. Randomized: 40 No. Excluded: 44 Not Meeting Inclusion Criteria: 41 Refused to Participate: 2 Other Reasons: 1 Allocated to Buprenorphine: 20 Received Buprenorphine: 20 Allocated to Detox/placebo: 20 Received Detox/Placebo:20 Included in Analysis:20 Excluded from Analysis: 0 Included in Analysis * :20 Excluded from Analysis: 0 All Patients: Group CBT Relapse Prevention Weekly Individual Counseling Three times Weekly Urine Screens Buprenorphine Maintenance vs. Detoxification Kakko J et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 361(9358):662-8, 2003.

Treatment duration (days) Remaining in treatment (nr) Detox/placebo Buprenorphine Maintenance vs. Detoxification: Retention

 2 =5.9; p=0.0150/20 (0%)4/20 (20%)Dead Cox regressionBuprenorphineDetox/Placebo Maintenance vs. Detoxification: Mortality Kakko J et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 361(9358):662-8, 2003.

Buprenorphine Implants for Opioid Addiction Ling et al., 2010

START Study Schema 1920Number screened for participation 1269Randomized 740Buprenorphine/Naloxone529Methadone 340Evaluable 400 Failed to remain on assigned medication for 24 wks 0Failed to provide ≥ 4 LT samples 391Evaluable 136Failed to remain on assigned medication for 24 wks 2Failed to provide ≥ 4 LT samples 261 Completed 32-week follow-up330 Completed 32-week follow-up

Treatment Retention

Treatment Retention by Dose

Opiate Positives by Dose

HIV Injection Risk Behavior Risk Behavior Survey completed at baseline, week 12, week 24 Risk Behavior Survey completed at baseline, week 12, week 24 Needle Sharing in Past 30 Days among Week 24 Completers: Baseline (%)Week 24 (%)p Bup/Nx (n=340) <.0001 MET (n=391) <.0001

HIV Sexual Risk Behavior Risk Behavior Survey completed at baseline, week 12, week 24 Risk Behavior Survey completed at baseline, week 12, week 24 Multiple Sexual Partners in Past 30 Days among Week 24 Completers: Baseline (%)Week 24 (%)p Bup/Nx (n=340)6.85.2<.04 MET (n=391)8.25.1<.04

MAT for Opioid Addiction Methadone and Buprenorphine Conclusions Relapse rates are high without MAT Relapse rates are high without MAT Methadone and Buprenorphine both efficacious and reduce mortality Methadone and Buprenorphine both efficacious and reduce mortality Methadone and Buprenorphine both reduce HIV risk behaviors Methadone and Buprenorphine both reduce HIV risk behaviors